News & Updates
Filter by Specialty:
Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
Among advanced hepatocellular carcinoma patients being treated with immune checkpoint inhibitors (ICIs), the occurrence of multisystem and more severe immune-related adverse events is a favourable signal, being associated with survival advantage, according to a Singapore study.
Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
08 Mar 2022
Adding capecitabine to adjuvant chemo improves 15-year OS in early breast cancer
Adding capecitabine to adjuvant chemotherapy containing docetaxel, epirubicin and cyclophosphamide significantly improves 15-year overall survival (OS) in patients with early breast cancer, results of the phase III FinXX trial (Finland Capecitabine Trial) have shown.
Adding capecitabine to adjuvant chemo improves 15-year OS in early breast cancer
07 Mar 2022
AChEI use ups lung cancer risk in older, comorbid patients
Medication with acetylcholinesterase inhibitors (AChEI) increases the risk of lung cancer among older patients and those with several comorbidities, reports a recent study.
AChEI use ups lung cancer risk in older, comorbid patients
07 Mar 2022
T2D risk elevated in thyroid cancer patients after thyroidectomy
Development of type 2 diabetes (T2D) is more likely to occur among patients with thyroid cancer who underwent thyroidectomy than matched controls, a Korea study has shown. In addition, a U-shaped dose-dependent relationship exists between the levothyroxine dosage and T2D risk.
T2D risk elevated in thyroid cancer patients after thyroidectomy
05 Mar 2022
Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC
In patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations*, combining niraparib with abiraterone acetate plus prednisone (AAP) in the first-line setting improved radiographic progression-free survival (rPFS) and other outcomes, results of the phase III MAGNITUDE study showed.